Sangamo plunges 38% after Pfizer ends agreement on hemophilia A gene therapy

pictafolio Sangamo Therapeutics ( NASDAQ: SGMO ) is down ~38% in after-hours trading Monday after announcing that Pfizer ( NYSE: PFE ) is returning the development and commercialization rights to hemophilia A gene therapy candidate giroctocogene fitelparvovec. Sangamo said Pfizer has decided not to pursue commercialization of.